Bharat Parenterals Ltd — Updates, 12-05-2025: Company Update

Bharat Parenterals Ltd. has announced a board meeting on the financial results for the quarter and half-year. The company delivered standalone revenue growth of 19.8% to ₹318.7 Cr in FY25, driven by stronger international market penetration and institutional clients. EBITDA rose 17% with stable margins, while net profit increased 17% to ₹26.58 Cr. Consolidated revenues grew 32% to ₹352.28 Cr, supported by Innoxel Lifesciences’ milestone income and Varenyam Healthcare’s consolidation, though EBITDA and net profit declined due to higher expenses from Innoxel’s pre-commercial phase and new acquisition costs. Innoxel advanced its complex injectables pipeline with multiple licensing deals and cleared a key US FDA inspection, setting the stage for commercial launches. The acquisition of Varenyam Healthcare bolsters domestic presence, with FY26 revenue growth expected. The company aims for improved standalone margins and operational break-even at Innoxel during FY26, supported by progressing regulatory and commercialization milestones.